On February 18, 2026, Representative Emily Kinkead formally introduced the Prescription Drug Copay Fairness Act (HB 2226) in the Pennsylvania House of Representatives. HB 2226 aims to stop harmful copay accumulator programs, which prevent manufacturer or charitable assistance from counting toward patients’ deductible and out-of-pocket limits.
If passed, the bill would update Pennsylvania’s consumer protection laws to make these practices unlawful and ensure that all forms of patient assistance including manufacturer coupons and charitable contributions count toward cost-sharing limits. HB 2226 has gained support from multiple cosponsors, reflecting strong bipartisan recognition of the financial burden these programs place on patients.
Read more about the bill and how Pennsylvania lawmakers are working to protect patients here: CBS Pittsburgh.
Please contact your state representative and ask them to sign on as a co-sponsor of HB2226!
Not sure who your state representative is? Find out here: Find My Legislator – The Official Website of the Pennsylvania General Assembly
Utilize the template below to contact your Pennsylvania State Representative:
Subject: Co-Sponsor Legislation Banning Co-Pay Accumulators
Dear Representative [Name Here},
As a constituent and advocate for patients living with chronic and serious health conditions, I urge you to sign on to the Prescription Drug Copay Fairness Act (HB 2226) introduced by Representatives Kinkead, Kuzma, Khan, Parker, and Hanbidge. This proposal would ensure that third‑party co-pay assistance counts toward patients’ out‑of‑pocket maximums and other cost‑sharing requirements, effectively banning co-pay accumulator adjustment programs. These programs place additional financial strain on people who already struggle to afford the care and therapies they need to manage their conditions.
People managing chronic or complex health conditions often rely on specialized treatments and medications that can be costly, even with insurance. Many depend on third‑party co‑pay assistance to access their prescribed therapies and maintain their health.
Co‑pay accumulator adjustment programs prevent these third‑party payments from counting toward deductibles and out‑of‑pocket limits. As a result, patients face unexpectedly high costs at the pharmacy counter—costs that can lead to delayed treatment, skipped doses, or going without essential care altogether. This not only jeopardizes patients’ health and stability, but also increases the likelihood of more severe health complications and higher long‑term costs.
Managing a chronic condition is already challenging. While insurers and manufacturers shift responsibility, patients and families bear the financial and health consequences.
I strongly urge you to support your constituents in the bleeding disorders community by cosponsoring the Prescription Drug Copay Fairness Act (HB2226) to ensure that all copays count. This link will take you to Representative Kinkead’s cosponsor memo: https://www.palegis.us/house/
Sincerely,
[Your Name]
[City] [State]